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Background: Intermittent preventive treatment in pregnancy has not been evaluated outside of Africa. Low
birthweight (LBW, <2,500 g) is common in Papua New Guinea (PNG) and contributing factors include malaria
and reproductive tract infections.
Methods: From November 2009 to February 2013, we conducted a parallel group, randomised controlled trial in
pregnant women (≤26 gestational weeks) in PNG. Sulphadoxine-pyrimethamine (1,500/75 mg) plus azithromycin
(1 g twice daily for 2 days) (SPAZ) monthly from second trimester (intervention) was compared against sulphadoxine-
pyrimethamine and chloroquine (450 to 600 mg, daily for three days) (SPCQ) given once, followed by SPCQ placebo
(control). Women were assigned to treatment (1:1) using a randomisation sequence with block sizes of 32. Participants
were blinded to assignments. The primary outcome was LBW. Analysis was by intention-to-treat.
Results: Of 2,793 women randomised, 2,021 (72.4%) were included in the primary outcome analysis (SPCQ: 1,008;
SPAZ: 1,013). The prevalence of LBW was 15.1% (305/2,021). SPAZ reduced LBW (risk ratio [RR]: 0.74, 95% CI: 0.60–0.91,
P = 0.005; absolute risk reduction (ARR): 4.5%, 95% CI: 1.4–7.6; number needed to treat: 22), and preterm delivery (0.62,
95% CI: 0.43–0.89, P = 0.010), and increased mean birthweight (41.9 g, 95% CI: 0.2–83.6, P = 0.049). SPAZ reduced
maternal parasitaemia (RR: 0.57, 95% CI: 0.35–0.95, P = 0.029) and active placental malaria (0.68, 95% CI: 0.47–0.98,
P = 0.037), and reduced carriage of gonorrhoea (0.66, 95% CI: 0.44–0.99, P = 0.041) at second visit. There were no
treatment-related serious adverse events (SAEs), and the number of SAEs (intervention 13.1% [181/1,378], control
12.7% [174/1,374], P = 0.712) and AEs (intervention 10.5% [144/1,378], control 10.8% [149/1,374], P = 0.737) was
similar. A major limitation of the study was the high loss to follow-up for birthweight.
Conclusions: SPAZ was efficacious and safe in reducing LBW, possibly acting through multiple mechanisms including
the effect on malaria and on sexually transmitted infections. The efficacy of SPAZ in the presence of resistant parasites
and the contribution of AZ to bacterial antibiotic resistance require further study. The ability of SPAZ to improve
pregnancy outcomes warrants further evaluation.
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Infants born with low birthweight (LBW, <2,500 g) due
to pre-term delivery (PTD, <37 weeks) and/or fetal
growth restriction are at increased risk of morbidity and
mortality [1,2]. Malaria in pregnancy is an important
cause of fetal growth restriction, PTD, and adverse birth
outcomes (miscarriage, stillbirth) [3], primarily due to
inflammatory processes secondary to sequestration of
Plasmodium falciparum (P.f.)-infected red blood cells in
the placenta [4]. Many women with placental malaria are
asymptomatic and such an infection can be undetectable
by peripheral blood examination [2]. In areas of moderate-
to-high endemicity, primigravidae are most at risk [5].
The burden of malaria and LBW is highest in low-
income countries and, worldwide, 125.2 million pregnant
women were at risk of infection in 2007 [6].
Intermittent preventive treatment of malaria in preg-
nancy (IPTp), namely the periodic administration of a
curative dose of an antimalarial, provides intermittent
chemoprophylaxis and clears asymptomatic infections.
The World Health Organisation recommends monthly
courses of sulphadoxine-pyrimethamine (SP) from second
trimester in areas of Africa with moderate-to-high malaria
transmission [7]. Although IPTp-SP remains generally
efficacious, increasing drug resistance has generated a
need for new IPTp candidates [8,9]. Azithromycin (AZ)
is an azalide antibiotic with favourable antimalarial
properties and a good safety profile in all trimesters of
pregnancy [10]. AZ combined with SP (SPAZ) reduced
PTD and malaria at delivery in one study in Malawi
[11,12]. Further, AZ has the potential to simultaneously
clear sexually transmitted infections (STIs) and reproduct-
ive tract infections that are known to increase the risk of
PTD and adverse pregnancy outcomes [13]. The antimal-
arial effect of AZ has been associated with blood levels at
96 h, and doses of 4 to 4.5 g over 2 to 3 days appear to be
required to obtain appropriate levels [10,14,15].
To date, IPTp has been studied only in Africa, where
P.f. predominates, and IPTp use outside of Africa is
currently not endorsed by the World Health Organisa-
tion [7]. However, many pregnant women elsewhere are
at risk of malaria in areas, such as Papua New Guinea
(PNG), where both P.f. and P. vivax (P.v.) are endemic
[3,16]. P.v. also causes adverse pregnancy outcomes,
through less well understood mechanisms [17].
We evaluated the efficacy and safety of IPTp with
SPAZ to prevent LBW and to reduce the prevalence of
malaria and anaemia at delivery in PNG.
Methods
Ethics
Ethical approval for the study protocol (Additional file 1)
was obtained from the PNG Institute of Medical Research
(PNGIMR) Institutional Review Board, the PNG MedicalResearch Advisory Council, and the Melbourne Health
Human Research Ethics Committee. The trial was regis-
tered with the United States National Institutes of Health
Clinical Trials Registry (NCT01136850, registered 06
April 2010) and has been reported according to CON-
SORT guidelines (Additional file 2). Because there is
currently insufficient evidence to support a general
recommendation for the use of IPTp-SP outside Africa
[7], and because SP alone is often ineffective against
P.v. [18], which causes around 40% of malaria infections
in PNG, we compared SPAZ-IPTp to a single course of
SP and chloroquine (CQ) to eliminate infection. The
study was conducted in accordance with Good Clinical
Practice guidelines (ICH GCP E6). External monitoring
was provided by one independent monitor and the Data
Safety Monitoring Board (DSMB). All participants provided
informed written consent. The legal age of consent for
women in PNG is 16 years. The trial was registered in April
2010, after 336 women had joined the study, as a result of
miscommunication between the principal investigator and
the on-site clinical team.
Interventions
The trial had two treatment arms with a 1:1 allocation
ratio. In the intervention arm, women received three
courses of SP (3 tablets [500/25 mg] given once, Micro
Labs Ltd., India) and AZ (2 tablets [500 mg] twice daily
for 2 days, Pfizer, USA), at minimum intervals of 4 weeks.
Women assigned to the control arm received one course
of SP (3 tablets, 500/25 mg) and CQ (3 or 4 tablets
[150 mg], daily for 3 days, Medopharm, India) at enrol-
ment, followed by monthly courses of placebo equivalent
(J. Bonal S.A., Spain). Women who did not already own
an insecticide-treated net were given one at enrolment if
available; local stock-outs meant that 8% of women did
not own, or receive, bed nets.
Intake of SP and the first of four doses of AZ (1 g; inter-
vention arm), and intake of SP (or placebo equivalent) and
the first of three doses of CQ (or placebo equivalent; con-
trol arm) was supervised at an antenatal clinic. Drugs were
administered with dry biscuits, and women were observed
for a minimum of 30 minutes following ingestion of study
medications. Treatment was rescheduled for first trimester
pregnancies and women with a positive malaria rapid
diagnostic test. Adherence to the remaining three doses of
AZ or two doses of CQ (or CQ placebo equivalent) for
first and second courses was assessed retrospectively at
second and third study visits, respectively, through help of
a questionnaire. Drug levels were not taken.
Objectives and outcome measures
The primary objective was to compare efficacy of IPTp
with SPAZ with a single treatment course of SPCQ to
prevent LBW.
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live born, singleton infants without congenital malforma-
tions with LBW. Secondary outcome measures included
mean birthweight, the proportion of women with malaria
and anaemia at delivery, and the proportion of women
who delivered a preterm infant. Safety outcomes included
the number of adverse events (AEs) and, specifically, the
number of maternal deaths, stillbirths, neonatal deaths,
and infants with congenital abnormalities.Trial design, setting, and participants
We conducted a single-blinded block-randomised con-
trolled trial.
The control arm was adapted from the policy for
prevention of malaria in pregnancy in PNG when the
trial was designed, which involved clearance of infec-
tion with a single dose of SP plus CQ for 3 days at first
antenatal visit, followed by weekly doses of CQ until
delivery (PNG standard of care) [16]. Because P.f. is
highly resistant to CQ in PNG [19,20], and compliance
was poor, we instead endeavoured to provide all partici-
pants with insecticide-treated nets. To allow for partici-
pant blinding, women assigned to control treatment
were provided placebo doses of SPCQ at subsequent
study visits. A previous survey of molecular markers of
SP resistance in children from the study area demon-
strated absence of ‘high’ and ‘super’ resistant P.f. and a
low prevalence of the dhps K540E mutation (20%)
[18,21]. The dose and regimen for AZ was selected based
on previous pharmacokinetic and tolerability studies [10],
and to give adequate drug levels at 96 hours to clear P.f.
and P.v. [14,22].
Pregnant women were enrolled between 23 November
2009 and 15 August 2012 at nine antenatal clinics in the
Madang and Sumkar districts of Madang Province, PNG
(Additional file 3). Pregnancy outcome follow-up was
concluded on 28 February 2013. Participating health
facilities with labour wards included Modilon General
Hospital, Yagaum Hospital, and the health centres in
Alexishafen and Mugil.
In a 2006 survey at one of the participating health
centres, prevalence at first antenatal visit of P.f. and P.v.
was 30.3% and 8.1% (by light microscopy), respectively,
and the prevalence of LBW amongst women not using
insecticide-treated nets was 17% (unpublished data).
The study area experiences year-round malaria trans-
mission and was considered hyper-endemic at the time
the trial was designed [23]. Chlamydia trachomatis,
Neisseria gonorrhoeae, and syphilis are thought to be
common in pregnant women in PNG [24]. Antenatal
HIV prevalence at the provincial hospital (Modilon
General Hospital) was 1.1% (2009 – 2012, unpublished
audit data).Screening, enrolment, and follow-up procedures
Community campaigns were held to raise awareness of
the trial. All pregnant women presenting for their first
antenatal visit at participating health centres were invited
to attend group information sessions and were screened.
Interested women were excluded if they had i) gesta-
tion >26 weeks by abdominal palpation, ii) haemoglo-
bin <6 g/dL and symptomatic as a result of anaemia,
iii) previous serious adverse reaction to study medications,
iv) permanent disability and chronic medical conditions, v)
known multiple pregnancy, vi) unavailable for follow-up,
or vii) age <16 years. We collected detailed information on
reasons for non-inclusion at screening for a subset of ante-
natal recruitment clinic sessions (n = 279), during which
30.8% (860/2,793) of all women randomised to treatment
were enrolled. Due to logistic constraints, we were unable
to gather demographic and clinical background data on
women who were screened but not enrolled. Written
informed consent was obtained, a focussed clinical exam-
ination performed, and socio-demographic and clinical
data collected using standardised case report forms. A
venous blood sample was taken and peripheral blood
smears were prepared. Women with malaria symptoms
and/or haemoglobin <9 g/dL (HemoCue Ltd, Angelholm,
Sweden; accuracy of 0.1 g/dL) were tested using a malaria
rapid diagnostic test (CareStart™ P.f/Pan combo, Access-
Bio, USA). Anaemia and malaria were treated with iron/
folate supplements and albendazole, and quinine (in first
trimester, 300 mg, 2 tablets orally 3 times daily for 7 days)
or artemether-lumefantrine (in second and third trimes-
ters, 20/120 mg, 4 tablets 6 times over 3 days), as per
national protocol [25]. Women treated for malaria had
their study medication administration rescheduled 2 weeks
later. Women were screened for syphilis (Syphicheck-WB,
QualPro, India) and treated with 2.4 MU of benzathine
penicillin G if found positive.
We were able to offer a sub-set of participants an
obstetric ultrasound (Logiqbook XP, General Electric
Medical Systems, UK) within a week of enrolment;
technical problems with our ultrasound machine pre-
cluded scanning for the entire trial period. Fetal biom-
etry alone was used to estimate gestational age (GA),
as the majority of women were unable to report their
last menstrual period and/or menstrual cycle charac-
teristics, and Ballard scores correlated poorly with GA
in our cohort. For women presenting early, GA was
estimated as per British Medical Ultrasound Guidelines
[26]. Women who had their first scan after mid-second
trimester had their GA estimated according to Hadlock
et al. [27]. The earliest scan available for each woman
was selected to estimate GA at delivery. At subsequent
scheduled study visits, peripheral blood smears and
samples were collected, and routine antenatal examin-
ation performed.
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swab was obtained for testing for C. trachomatis, N.
gonorrhoeae, and Trichomonas vaginalis for a subset of
women. Once available, participants were notified of
results and referred for treatment.
Participants were followed-up until delivery, and birth-
weights measured by study nurses to the nearest 10 g
using digital infant scales (Cupid 1, Charder Medical,
Taiwan). Time elapsed between birth and birthweight
measurements was documented, and newborns were
checked for congenital abnormalities. Deliveries <22 ges-
tational weeks were categorised as miscarriages. Maternal
haemoglobin was measured, peripheral blood placental
impression and cord blood smears prepared, and placental
biopsies were taken. Women were invited to re-attend
at 4 to 6 weeks postpartum with their baby. A team of
community liaison officers, reporters, and nurses was
dedicated to the follow-up of women who did not
present for delivery at a participating health centre
within one month of the estimated delivery date in
order to establish pregnancy outcome.Adverse events monitoring and reporting
Case report forms were completed for maternal and
neonatal AEs detected at scheduled antenatal and post-
partum visits, at delivery, and during non-scheduled
visits. The study clinician on-call was alerted by the
nursing team upon detection of a possible serious
adverse event (SAE), whereby cases were clinically
evaluated and reported shortly thereafter, but allowing
for a maximum time frame of 24 hours for reporting of
cases detected at distal study sites. AEs were considered
SAEs if fulfilling one of the following criteria: the event
resulted in death, was a congenital abnormality, resulted
in hospitalisation or prolongation of existing hospi-
talisation, was life-threatening, resulted in persistent/
significant disability, or was deemed serious for other
medically significant reasons by the study physicians.
SAE reports were completed for mothers who experienced
miscarriages or stillbirths. Analysis of all AEs was by
actual drugs received (hence adjusted for crossover)
and included all women who received trial medications
(n = 2,752). Drug-related AEs represented drug side effects.
Reports of side effects at each treatment course (includ-
ing placebo administration in the control arm) were
considered as separate AEs.
A detailed report of each SAE was sent immediately
to the DSMB, and the Malaria in Pregnancy Consor-
tium and Pfizer drug safety groups. Assessments of
the relationship between AEs and study medication
were undertaken by the investigators and reports for-
warded to the DSMB and an independent clinician for
scrutinisation.Laboratory evaluations
Labelled blood and impression smears were air-dried and
stained with 4% Giemsa for 30 minutes. Thick smears
were used to count the number of asexual parasites per
200 leukocytes (or per 500 if <10 parasites/200 leuko-
cytes), assuming 8,000 leukocytes/μL of blood; slides were
declared negative if no parasite was seen in 200 oil-
immersion fields. Two microscopists read each slide, and
third reads were performed to resolve discrepant results.
When species discrepancies remained after third reads,
qPCR was performed on maternal venous blood, and
these results were considered definitive [28]. A sample of
10 mL of venous blood was collected from each partici-
pant at both enrolment and delivery into Lithium Heparin
vacutainers (BD, USA), and plasma was separated and
stored at −80°C until further analyses. Light microscopy
and qPCR were undertaken at the PNGIMR. Vaginal swabs
were stored, extracted, and analysed by qPCR for presence
of beta globin (positive control), C. trachomatis, N. gonor-
rhoeae, and T. vaginalis as described elsewhere [29].
A placental biopsy (2.5 × 2.5 × 1 cm) was collected and
included the thickness of the placenta from the maternal
to the fetal side without reaching the fetal membrane.
Biopsies were stored at room temperature in 10% neutral
buffered formalin and trimmed to fit histology cassettes.
Cassettes were transported to Melbourne, Australia,
where they were wax embedded. Histological sections
were stained with Giemsa and coverslipped. Slides were
returned to the PNGIMR for analysis. A subset of 423
placental biopsies were read at CRESIB, Barcelona, Spain,
by Prof J Ordi, who also provided quality control on slide
reading. Placental malaria was staged according to the
presence/absence of three histological features: infected
erythrocytes, hemozoin in monocytes/macrophages, and
hemozoin in fibrin deposits [30,31]. Placental malaria was
classified as active (parasites detected) or past infection
(malaria pigment without parasites) [30,31].
Randomisation and masking
Following enrolment, women were randomly allocated
to SPCQ/placebo or SPAZ using a randomisation list
prepared by an independent statistician in Stata 10.0
(StataCorp, USA). Each treatment (SPCQ/placebo or
SPAZ) was randomly assigned to four different treat-
ment codes, resulting in a total of eight treatment codes
(letters A–H). A block randomisation procedure was
subsequently used, with blocks of 32, each containing
four women assigned to each treatment code. Study
drugs were packaged and labelled at the PNGIMR by
staff not involved in the trial, and allocation codes were
kept in a locked file cabinet offsite. Women were rando-
mised to treatment codes using pre-made, opaque, con-
secutively numbered envelopes. The treatment code was
revealed after completion of enrolment and immediately
Unger et al. BMC Medicine  (2015) 13:9 Page 5 of 16prior to treatment. Taste and colour of placebo and
active medication differed at times; enrolled women were
not told of their allocation, but it was impossible to blind
clinical staff directly involved with drug administration.
All other personnel (laboratory and administrative staff,
data entry clerks) were blinded to the assignments. The
allocation code was broken at completion of laboratory
analyses and upon finalisation of data collection, entry,
and cleaning. The statistical analysis was performed after
the database was locked, but was not blind to treatment
allocation.
Sample size calculations
The sample size calculation was based on the assump-
tion that SPAZ lowers the proportion of LBW babies by
30% compared to a single course of SP and CQ when
given in conjunction with insecticide-treated nets (12.0%
to 8.4%). Taking into consideration 20% loss to follow-up, a
power of 80%, and 95% confidence, 1,396 women per arm
were needed to demonstrate efficacy (Additional file 1).
Statistical analysis
Data was double-entered into case report form-specific
databases (FoxPro 9.0, Microsoft, USA). Individual data-
bases were merged and data analysed using Stata 12.0
(StataCorp, USA). Both intention-to-treat (ITT) and per-
protocol (PP) analyses were carried out for the primary
outcome (LBW), birthweight, malaria, and anaemia at
delivery. ITT analysis included all women randomised to
treatment, except those that were retrospectively excluded
because of incomplete consent forms. Women who expe-
rienced unintentional crossover were assessed by original
assigned groups. PP analysis only included women who
received two or three treatments without crossover. Safety
analyses were performed for all women who received
treatment, including those with incomplete consent
forms, and were done according to actual treatment
received at enrolment (adjusted for crossover). Women
with incomplete consent forms (lack of appropriate
signature, date, and/or witness if illiterate) had been
screened, had received counselling, had provided written
informed consent, and were randomised to treatment. As
per the trial monitor’s recommendations, these women
were retrospectively excluded from all trial analyses bar
those pertaining to drug safety.
Only birthweights from singleton pregnancies of live
births ≥22 weeks’ gestation with no congenital abnormal-
ity and measured within 7 days of delivery were included
in birthweight analyses [32].
To assess the distribution characteristics of continuous
variables, data were graphed as a kernel density plot
including a normal density and the Shapiro-Wilk test was
performed. Linearity of continuous data was assessed
through visual inspection of scatter plots. Univariatecomparisons of variables were subsequently performed
using the χ2 test or Fisher’s exact test for categorical data,
the Student’s t-test or ANOVA for parametric data, and
Mann Whitney-U or Kruskal-Wallis tests for nonpara-
metric data. Unadjusted risk ratios (RR) were calculated
for primary and secondary categorical outcomes includ-
ing LBW, and difference in means were calculated for
continuous parametric data including birthweight and
haemoglobin. P <0.05 was considered significant.
All factors with a tendency for association with LBW
when analysed univariately (defined as P <0.1) were
included in a multivariable Poisson regression model with
robust error variance as a starting model for a backward
stepwise elimination model selection procedure [33]. A
multivariable linear regression was used to calculate an
adjusted difference in mean birthweight. Multivariate
analyses for LBW/birthweight were performed in order
to validate the effect of drug treatment on the primary
outcome observed in crude analysis. For women with
known pregnancy outcome but missing birthweight,
multiple imputation was performed to derive estimated
birthweights by drawing 20 imputed data sets from a
Bayesian posterior predictive distribution of the missing
data [34].
A priori tests for interaction (defined as P <0.15 of
interaction term) between the intervention and gravidity
(categorised as primigravida, multigravida), bed net use
prior to enrolment (categorised as non-user, and user of
a bed net [untreated and treated combined]), maternal
height (categorised as low [<150 cm] and normal height
[≥150 cm]) and maternal ethnic grouping (categorised
as maternal highlander parentage and non-highlander
parentage) were performed on the final multivariable
model for LBW using the Wald test. Stratified analyses
for the primary outcome using the same variables were
undertaken.
Lastly, we estimated the population-attributable fraction
of LBW due to malaria using established methodology [1].
This calculation was based on the assumption that LBW
can only be attributed to malaria if there was evidence of
placental malaria (past or active infection).
Role of funding source and ethical approval
This trial was supported by the Malaria in Pregnancy
Consortium (funded by the Bill & Melinda Gates Foun-
dation, 46099), and the Pregvax Consortium (European
Union’s Seventh Framework Programme FP7-2007-
HEALTH, PREGVAX 201588, and the Spanish Govern-
ment EUROSALUD 208 Programme). Azithromycin was
provided by Pfizer Inc. as part of an Investigator-
Initiated Research grant (WS394663). Funding sources
did not have any involvement in study design, collection,
analysis, and interpretation of data, and compilation and
submission of this report.
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Of women screened at antenatal clinics, 2,793 were
enrolled between November 2009 and August 2012. The
trial flowchart is outlined in Figure 1: 18 women were
excluded due to incomplete consent forms, leaving 2,775
women (99.4%) in the ITT cohort at baseline. Their
demographic and clinical characteristics were similar
across treatment arms and are presented in Table 1.
Overall, 50.2% (1,390/2,770) of participants were primi-
gravida, 62.2% (1,720/2,764) resided in rural areas, 81.4%
(2,157/2,650) were anaemic (Hb <11 g/dL), and 7.4%
(204/2,766) had microscopy-detected malaria parasit-
aemia. The principal reason for exclusion at screening
was advanced GA (Figure 2).
Of women in the ITT cohort 81.0% (2,247/2,775) had
birth outcome information collected (follow-up completed
in February 2013), and 72.8% (2,021/2,775) had birth-
weights of congenitally normal live singletons measured
within 7 days of delivery and were therefore eligible for
inclusion in the primary outcome analysis. For 1,013
women who were randomised to SPAZ and included in
the ITT birthweight analysis, the mean number of doses
of SPAZ was 2.79 ± 0.5 (median 3, range 0–4). Women
who were excluded from the ITT birthweight analysis
(n = 754) were more commonly malaria infected at
baseline, had lower literacy, more commonly resided in
rural areas, and had lower fundal heights compared to
those included (Additional file 4), but had similar baseline
characteristics when assessed according to treatment arm
(Additional file 4). There was no significant difference in
the proportion of women excluded from ITT birthweight
analyses by trial arm (SPCQ 27.1% [374/1,382] vs. SPAZ
27.3% [380/1,393], P = 0.898; Figure 1; Additional file 4).
Amongst exclusions, 62.9% (474/754) of women were lost
for pregnancy outcome follow-up: their proportion did
not differ between treatment arms (SPCQ 16.8% [232/
1,382] vs. SPAZ 17.4% [242/1,393], P = 0.682).
The overall prevalence of LBW was 15.1% (305/2,021)
and the mean birthweight was 2,943 ± 479 g. Amongst
women who had pregnancy dating by ultrasound, 8.6%
(113/1,320) delivered preterm. Overall, 3.1% (63/2,045),
18.8% (278/1,472), and 7.4% (109/1,472) of women had
peripheral parasitaemia, placenta malaria (past and active),
and active placental malaria, respectively, and 74.4%
(1,389/1,868) were anaemic (Hb <11 g/dL) at delivery.
Compared to controls, women who received SPAZ had a
lower risk of LBW (RR: 0.74, 95% CI: 0.60–0.91, P = 0.005),
translating into an absolute risk reduction (ARR) of 4.5%
(95% CI: 1.4–7.6) and a number needed to treat of 22
(Table 2). Using imputed birthweights for 152 women with
pregnancy outcome but missing birthweight, the RR for
LBW with SPAZ was 0.74 (95% CI: 0.60–0.92, P = 0.007).
When adjusted for factors associated with LBW on univari-
ate analysis, such as infant gender, gravidity, bed net use,maternal height, and maternal ethnic origin (Additional
file 4), a similar RR (95% CI) was obtained: 0.72 (0.59–0.89;
P = 0.002; Table 2). PP analyses yielded comparable results
(Table 2).
Mean birthweight was 41.9 g higher (95% CI: 0.2–83.6;
P = 0.049) in the intervention arm, and when adjusted
for potential confounders a similar result was obtained
(52.4, 95% CI: 13.2–91.6, P = 0.009; Table 2). The observed
difference in mean birthweight was largely explained by
lower birthweights in the control compared to intervention
in first quartile of the overall birthweight distribution
(Mann Whitney-U test, P = 0.001; Figure 3). In a subset of
women who had ultrasound pregnancy-dating, a reduction
in PTD in the intervention arm was noted (RR: 0.62, 95%
CI: 0.43–0.89, P = 0.010; ARR: 4.0%, 95% CI: 1.0–7.0;
Table 2).
We observed no statistically proven interaction on LBW
between the intervention and gravidity (P = 0.728), bed
net use prior to enrolment (P = 0.172), maternal height
(P = 0.818), and maternal highlander parentage (P = 0.238).
Stratification for the aforementioned variables suggested
that women who benefitted most may have been those in
their first pregnancy, of low height, of highlander parentage,
and who reported bed net use at enrolment (Additional
file 4).
Women receiving the intervention were at lower risk of
peripheral (RR: 0.57, 95% CI: 0.35–0.95; P = 0.029; ARR:
1.7%, 95% CI: 0.1–3.2) and placental blood parasitaemia
(RR: 0.52, 95% CI: 0.28–0.97, P = 0.034; ARR: 1.6%, 95%
CI: 0.1–3.2) as well as active placental infection (RR: 0.68,
95% CI: 0.47–0.98, P = 0.037; ARR: 2.9%, 95% CI: 0.2–5.5;
Table 3). There was no significant difference in mean Hb
or in proportion of women with anaemia (Table 3). The
population-attributable fraction of LBW due to malaria
was estimated at 7.4% overall, and 0.9% and 12.1% in the
intervention and control arms, respectively.
In self-collected vaginal swabs obtained from a subset of
participants at second visit, carriage of N. gonorrhoeae was
lower in women receiving SPAZ (SPCQ 8.2% [55/674] vs.
SPAZ 5.4% [37/688], RR: 0.66, 95% CI: 0.44–0.99,
P = 0.041), while carriage of C. trachomatis (SPCQ 4.5%
[30/674] vs. SPAZ 3.8% [26/688], RR: 0.85, 95% CI: 0.51–
1.42, P = 0.532) and T. vaginalis (SPCQ 21.8% [147/674]
vs. SPAZ 21.5% [148/688], RR: 0.99, 95% CI: 0.81–1.21,
P = 0.894) did not differ significantly.
We detected 204 maternal and 151 neonatal SAEs,
none of which were drug-related and there were no sig-
nificant differences in numbers between treatment
groups (Table 4). There were three maternal deaths (all
due, or probably due, to postpartum haemorrhage). We
did not observe significant differences in the proportion
of maternal deaths, miscarriages, stillbirths, congenital
abnormalities, and neonatal deaths between trial arms
(Table 4).
Figure 1 Trial profile. IPTp, Intermittent preventive treatment in pregnancy; SP, Sulphadoxine-pyrimethamine; CQ, Chloroquine; AZ, Azithromycin;
ITT, Intention-to-treat analysis; PP, Per protocol analysis.
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Table 1 Baseline characteristics of study participants
Characteristic Control (SPCQ and placebo) Intervention (SPAZ)
(n = 1,382) (n = 1,393)
Age, years 24.5 [5.4] 24.4 [5.5]
Height, cm; n = 2,729 154.3 [6.0] 154.1 [5.8]
Body mass index, kg/m2; n = 2,721 22.8 [2.9] 22.8 [2.9]
Mid-upper arm circumference, cm; n = 2,714 23.9 [2.5] 24.0 [2.6]
Fundal height, cm; n = 2,771 21.1 [4.2] 21.0 [4.3]
Haemoglobin (Hb), g/dL; n = 2,650 9.7 [1.5] 9.7 [1.5]
Anaemia, Hb <11 g/dL 1,058/1,313 (80.6) 1,099/1,337 (82.2)
Syphilis 15/1,122 (1.3) 20/1,166 (1.7)
No. of previous pregnancies
0 681 (49.4) 709 (51.0)
1 292 (21.2) 279 (20.1)
≥2 406 (29.4) 403 (29.0)
Previous adverse pregnancy outcome 103/1,375 (7.5) 119/1,389 (8.6)
Used bed net before enrolment (2 wks)
Not used 322 (23.4) 347 (25.0)
Used, without insecticide 588 (42.7) 561 (40.4)
Used, insecticide treated 466 (33.9) 481 (34.6)
Given new bed net at enrolment 873/1,375 (63.5) 849/1,385 (61.3)
Used antimalarials in this pregnancy 146/1,340 (10.9) 161/1,366 (11.8)
Peripheral parasitaemia by microscopy
Any speciesa 100/1,376 (7.3) 104/1,390 (7.5)
Plasmodium falciparum 87 (6.3) 90 (6.5)
Plasmodium vivax 11 (0.8) 12 (0.9)
Smoker 249/1,380 (18.0) 275/1,392 (19.8)
Rural residence 844/1,375 (61.4) 876/1,389 (63.1)
Literate 1,223/1,376 (88.9) 1,248/1,391 (89.7)
Income-generating activity (woman) 728/1,304 (55.8) 729/1,326 (55.0)
Income-generating activity (partner) 939/1,358 (69.2) 947/1,378 (68.7)
Highlander parentage 99/1,380 (7.2) 78/1,393 (5.6)
Data are mean [standard deviation], or number (%).
aIncludes two P. malariae in the control, and one P. malariae, one P. ovale, and one mixed P. falciparum and P. ovale infections in the intervention group.
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number of drug-related AEs did not differ between treat-
ment groups, despite the fact that women in the control
arm received placebo following their baseline treatment
course (P = 0.737; Table 4). Amongst women reporting
drug-related AEs, common side effects included vomiting
(5.7%; 156/2,752), dizziness (3.2%; 89/2,752), nausea (2.9%;
80/2,752), itching (1.0%; 26/2,752), weakness (1.0%; 26/
2,752), and abdominal pain (0.6%; 15/2,752). Women re-
ceiving control treatment more frequently experienced diz-
ziness (P = 0.013) and abdominal pain was more commonly
reported by women who had SPAZ (P = 0.021; Table 4).
Amongst women in the SPAZ arm, there was no differ-
ence in the proportion of women-infant pairs affected byat least one SAE (1 treatment: 14/117 [12.0%], 2 treat-
ments: 23/223 [10.3%], 3+ treatments: 122/1,038 [11.8%],
P [comparison across groups] = 0.821), and there was
no difference across groups when maternal SAEs (1 treat-
ment: 13/117 [11.1%], 2 treatments: 15/223 [6.7%],
3+ treatments: 75/1,038 [7.2%], P [comparison across
groups] = 0.285) and neonatal SAEs (1 treatment: 4/117
[3.4%], 2 treatments: 12/223 [5.4%], 3+ treatments: 60/
1,038 [5.8%], P [comparison across groups] = 0.567) were
evaluated separately. Similarly, the proportion of women-
infant pairs affected by at least one SAE did not differ sig-
nificantly by number of treatment visits in the control arm
(1 visit: 14/144 [9.7%], 2 visits: 17/224 [7.6%], 3+ visits:
116/1,006 [11.5%], P [comparison across groups] = 0.208).
Figure 2 Detailed screening data for 279 clinic sessions (held at nine antenatal clinics) during which 860 of 2,793 trial participants
(30.8%) were recruited.
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related AE increased with number of doses received,
both for SPAZ (1 dose: 4/117 [3.4%], 2 doses: 15/223
[6.7%], 3+ doses: 116/1,038 [11.2%], P = 0.007) and
SPCQ/placebo (1 dose: 7/144 [4.9%], 2 doses: 12/224
[5.4%], 3+ doses 127/1,006 [10.6%], P <0.001). Only 1.9%
(47/2,466) and 1.1% (24/2,133) of women reported not
taking the remaining doses of the treatment courses
provided at enrolment and second study visit courses
(AZ or CQ/placebo CQ), respectively. There were no
significant differences in adherence between treatment
arms (enrolment treatment course: intervention 1.8%
[22/1,255] vs. control 2.1% [25/1,211], P = 0.572; second
visit treatment course: intervention 1.2% [13/1,081] vs.
control 1.1% [11/1,052], P = 0.446).
Discussion
We found that IPTp with SPAZ significantly reduced the
risk of LBW and PTD, and increased mean birthweight
compared to a single treatment course of SPCQ. Both
treatments were well tolerated.
To our knowledge, this is the first successful trial of
IPTp outside of sub-Saharan Africa, or in an area where
both P.f. and P.v. are endemic. The intervention reduced
malaria infection at delivery, yet overall prevalence was
substantially lower than previously reported [23]. IPTp
with SPAZ appears to be beneficial against malaria insettings like PNG, although there were too few P.v.
infections to evaluate the effect of the intervention on
these. HIV infection is uncommon in Madang, precluding
assessment of SPAZ in HIV-infected women.
Few participants reported problems with adherence to
either study regime, despite the high dose of AZ. We
only observed the first dose of each treatment course,
and did not measure drug levels, hence non-adherence
may be underestimated. The proportion of women
reporting side effects in the intervention arm was small,
despite the high dose of azithromycin (4 g) compared to
other trials of IPTp testing AZ-based combinations
[11,15,35]. This might be due to our split daily dosing,
choice of partner drug for AZ, and provision of a dry
biscuit prior to treatment at the antenatal clinic. Fur-
thermore, the number of episodes during which women
reported side-effects were similar between both groups,
even though women randomised to the control arm had
received placebo medication at follow-up visits.
The beneficial effect of SPAZ on LBW and placental
malaria may, in part, be because of an imbalance in trial
design as women in the intervention arm received more
SP doses. Our control group was designed to match the
current PNG protocol when the trial was designed.
Although PNG policy now advocates three monthly
doses of SP, a direct comparison with this regime is not
possible: the impact of monthly SP on LBW in PNG is
Table 2 LBW, preterm delivery, and mean birthweight, by treatment group
Outcome ITT analysis PP analysis
Control (SPCQ
and placebo)
Intervention
(SPAZ)
Risk ratio or Δ
mean (95% CI)
P Control (SPCQ
and placebo)
Intervention (SPAZ) Risk ratio or Δ
mean (95% CI)
P
LBW (Birthweight < 2,500 g), unadjusted 175/1,008 (17.4) 130/1,013 (12.8) 0.74 (0.60–0.91) 0.005 159/952 (16.7) 122/967 (12.6) 0.76 (0.61–0.94) 0.011
LBW (Birthweight < 2,500 g), adjusteda – – 0.72 (0.59–0.89) 0.002 – – 0.72 (0.58–0.89) 0.003
Birthweight (g) 2,921.6 2,963.5 41.9 0.049 2,928.7 2,967.9 39.2 0.068
unadjusted [2,890.1–2,953.1] [2,936.0–2,991.0] (0.2–83.6) [2,986.9–2,960.4] [2,940.3–2,995.4] (−2.8–81.2)
Birthweight (g) 2,916.6 2,969.0 52.4 0.009 2922.9 2974.1 51.2 0.011
adjustedb [2,888.8–2944.3] [2,941.4–2,996.6] (13.2–91.6) [2,895.0–2,950.9] [2,946.4–3,001.8] (11.7–90.6)
PTD (<37 GWs), n (%), unadjusted,
best available dating ultrasound
69/652 (10.6) 44/668 (6.6) 0.62 (0.43–0.89) 0.010 63/622 (10.1) 40/651 (6.1) 0.61 (0.41–0.89) 0.009
Data are number (%) or mean [95% CI], unless stated otherwise; ITT, Intention-to-treat; PP, Per-protocol; GW, Gestational weeks; CI, Confidence interval. P <0.05 marked in bold.
aAdjusted for infant gender, gravidity, no. of treatment courses (ITT only), clinic location, season of delivery, bed net use, mid-upper arm circumference, height, maternal highlander heritage.
bAdjusted for infant gender, gravidity, no. of treatment courses (ITT only), clinic location, mid-upper arm circumference, height, maternal highlander heritage.
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Figure 3 Cumulative frequency (a) and Kernel density plot (b)
of birthweight, by trial arm (ITT analysis).
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three or more doses of SP are better than one or two for
the prevention of malaria and LBW in African women
[36]. If SPAZ were compared to monthly SP, the effect
on LBW might be less striking. SP has not been shown
to prevent PTD [37], which was significantly less fre-
quent in women receiving SPAZ than SPCQ. The small
number of women who received only one course of
SPAZ or SPCQ and were followed up for the primary
outcome (n = 75) precludes further analysis to quantify
the benefit of adding AZ to SP. Interaction and stratified
analyses did not indicate a difference in the efficacy of
treatment by gravidity: the study was not powered and
was not designed to convincingly demonstrate this.
The low overall prevalence of malaria (and low popu-
lation attributable fraction of LBW due to malaria), as
well as the reduction in PTD in the intervention arm,
suggests that the effect of SPAZ on reducing LBW is
mediated by other mechanisms in addition to its anti-
malarial effect. A greater impact on LBW might be
observed in settings where malaria prevalence is higher
than in this study, and women share other common risk
factors. SPAZ may prevent LBW by clearing STIs andascending reproductive tract infections [22], which are
common in PNG [24]. Vaginal swabs were collected
from a subset of 400 study participants at enrolment. Of
these, 11% carried C. trachomatis, and 10% carried N.
gonorrhoeae [29]. There were only modest differences in
carriage of C. trachomatis and N. gonorrhoeae at second
treatment visit between women receiving SPAZ and
SPCQ. Carriage of N. gonorrhoeae was lower in women
receiving SPAZ, while carriage of C. trachomatis did not
differ significantly by treatment arm. This suggests that
an impact on STI carriage explains only a part of the
positive effect of SPAZ on LBW. AZ may also exert
immunomodulatory effects favouring fetal growth [38].
Two previous studies of SPAZ-IPTp in rural Malawi
gave conflicting results. In one, monthly SP and 1 g of AZ
given twice reduced the risk of PTD, LBW, and malaria
compared to two doses of SP, to a similar extent to our
study [11,12]. In the other, addition of AZ 1 g twice to
three doses of SP-IPTp did not significantly reduce PTD
or malaria; LBW was not reported and mean birthweight
was 40 g higher in the AZ arm [35]. Both studies used
lower doses of AZ than our trial (4 g). Taken together, the
studies suggest SPAZ may have beneficial effects on PTD,
depending on the population characteristics.
One concern with use of SP is emergence of drug
resistance that limits efficacy or could even exacerbate in-
fection [39]. Parasites from this study have not been typed
for drug resistance markers, but contemporaneous parasites
from children and adults in the same locale have recently
been analysed [18]. ‘Highly resistant’ patterns of molecular
markers (quintuple mutations in the dhfr and dhps genes)
and ‘super resistant’ parasites (also featuring dhfr 164 or
dhps 581 mutations) [21] have not been detected, and the
prevalence of dhps 540 mutations associated with drug fail-
ure in young children [21] was <20%. By contrast, P.v. is
frequently resistant to SP [18], but was rare in this cohort.
Potential adverse consequences of AZ use may include
selection for (probably temporary) increases in carriage of
AZ-resistant organisms, especially Streptococcus pneumo-
niae [40], and a possible association between macrolide
use in late pregnancy and increased risk of infantile hyper-
trophic pyloric stenosis [41]. Such potential effects require
careful monitoring in future studies of AZ for indications
such as IPTp.
There are several limitations to our study. First, birth-
weights eligible for inclusion in the primary outcome
analysis were available for only 72% of women randomised
to treatment. Reassuringly, loss to follow-up rates did
not differ between control and intervention arm. Further-
more, there were no major differences in the background
characteristics of women that were lost to follow-up
when compared to those who were not (Additional
file 4). However, women lost to follow-up were more
likely to be young and malaria infected at enrolment. It
Table 3 Malaria infection and anaemia at delivery, by treatment groups
Outcome ITT analysis PP analysis
Control Intervention Risk ratio P Control Intervention Risk ratio P
(SPCQ and
placebo)
(SPAZ) (95% CI) (SPCQ and
placebo)
(SPAZ) (95% CI)
Peripheral blood
(light microscopy)
All infections 40/1,022 (3.9) 23/1,023 (2.3) 0.57 (0.35–0.95) 0.029 39/962 (4.1) 22/972 (2.3) 0.56 (0.33–0.93) 0.024
P. falciparum 29 (2.8) 18 (1.8) 0.62 (0.35–1.11) 0.104 28 (2.9) 17 (1.8) 0.60 (0.33–1.09) 0.090
P. vivax 11 (1.1) 5 (0.5) 0.45 (0.16–1.30) 0.142 11 (1.1) 5 (0.5) 0.45 (0.16–1.29) 0.127
Placental blood
(light microscopy)
All infections 29/847 (3.4) 15/841 (1.8) 0.52 (0.28–0.97) 0.035 28/800 (3.5) 14/803 (1.7) 0.50 (0.26–0.94) 0.028
P. falciparum 25 (3.0) 15 (1.8) 0.60 (0.32–1.14) 0.115 24 (3.0) 14 (1.7) 0.58 (0.30–1.12) 0.098
P. vivax 1 (0.1) 0 (0.0) – – 1 (0.1) 0 (0.0) – –
Cord blood (light microscopy)a 4/744 (0.5) 3/744 (0.4) 0.75 (0.17–3.34) 1.000 4/695 (0.6) 3/716 (0.4) 0.73 (0.16–3.24) 0.681
Placental malaria (histology)
Active and past infectionb 150/736 (20.4) 128/736 (17.4) 0.85 (0.69–1.06) 0.143 138/697 (19.8) 122/702 (17.4) 0.88 (0.71–1.10) 0.245
Active infectionc 65/736 (8.8) 44/736 (6.0) 0.68 (0.47–0.98) 0.037 62/697 (8.9) 41/702 (5.8) 0.66 (0.45–0.96) 0.029
Anaemia (Hb <11 g/dL) 689/935 (73.7) 700/933 (75.0) 1.02 (0.97–1.07) 0.508 647/883 (73.3) 663/889 (74.6) 1.02 (0.96–1.08) 0.532
Severe anaemia (Hb <7 g/dL) 44/935 (4.7) 37/933 (4.0) 0.84 (0.55–1.29) 0.432 39/883 (4.4) 34/889 (3.8) 0.87 (0.55–1.36) 0.531
Data are number (%). P <0.05 marked in bold.
aAll P. falciparum.
bDetection of parasites or malaria pigment.
cDetection of parasites.
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mation of the effect of SPAZ on LBW, given these
women are at higher risk of placental malaria [42], and
may be at higher risk of carrying bacterial STIs [43],
and so would benefit most from the intervention. Fur-
thermore, the reasons for not presenting for delivery
remain unknown for 474 women, which may include
AEs. Second, the proportion of primigravidae was high
(50.2%), suggesting that there was selection bias, which
could result in overestimating the effect SPAZ had on
LBW. Third, only one quarter of women screened were
ultimately enrolled and randomised, the principal reason
for exclusion being presentation at advanced GA. This
raises questions as to the representativeness of the
study sample. Due to logistic reasons, we were unable
to collect background demographic data for a substan-
tial proportion of those women that were screened but
not enrolled. It is possible that these women were more
likely to be multigravid, and were more likely to be
excluded because they tended to present at more
advanced gestation. This may result in overestimation
of the effect, although this could be less marked in
circumstances of relatively low malaria prevalence. Not
all women had ultrasound dating, and amongst those
who did, many presented relatively late: use of later
scans will underestimate GA in small-for-gestational-
age babies and overestimate GA in macrosomic babies.Reassuringly, there was a similar degree of reduction in
PTD in the SPAZ arm amongst women who had early
dating scans, although this was not statistically significant
(due to a lack of power) (SPCQ 6.6% [23/333] vs. SPAZ
3.9% [13/327], RR: 0.58, 95% CI: 0.30–1.12, P = 0.097). In
addition, we did not measure in detail some potentially
important confounders, including women’s socioeconomic
status. Lastly, due to funding constraints, we were unable
to evaluate the impact of treatment on reducing chor-
ioamnionitis, an important risk factor for PTD. Strengths
of the study include the large sample size, random group
allocation, the demonstration of benefit from IPTp in a
setting outside Africa, and the impact of SPAZ on
clinically-important endpoints of LBW and PTD.
The main reason for not meeting trial eligibility criteria
was advanced GA, and there was a treatment-independent
benefit of number of study visits in reducing LBW
(Additional file 4). The more often, and earlier, women
attend antenatal care, the more they will benefit from
interventions that may reduce the risk of LBW other
than IPTp, as well as maximise the benefit from IPTp
[36]. It is therefore of utmost importance that access to,
and early first attendance at, antenatal care is improved
whilst interventions to improve birth outcomes are
rolled out to prevent compromising the effectiveness of
IPTp. Women excluded from the primary outcome
analysis tended to be younger and were more likely to
Table 4 Safety of trial interventions: adverse events
Outcome Control (SPCQ and placebo)
n = 1,374
Intervention (SPAZ)
n = 1,378
Risk ratio (95% CI) P
All adverse events 414 (30.1) 397 (28.8) 0.96 (0.85–1.07) 0.447
All serious adverse events (SAE) 174 (12.7) 181 (13.1) 1.04 (0.85–1.26) 0.712
Maternala 100 (7.3) 104 (7.5) 1.04 (0.80–1.35) 0.788
No. admittedb 94 (6.8) 90 (6.5) 0.96 (0.72–1.26) 0.745
No. of mothers with 2 SAEs 4 (0.3) 1 (0.1) 0.25 (0.03–2.23) 0.218
No. drug-related SAEs 0 (0.0) 0 (0.0) – –
Characteristics of maternal SAEsc
Maternal death 1 (0.1) 2 (0.2) 1.99 (0.18–22.0) >0.999
Spontaneous abortion 4 (0.3) 1 (0.1) 0.24 (0.03–2.23) 0.218
Stillbirth 15 (1.1) 25 (1.8) 1.66 (0.88–3.14) 0.113
Emergency caesarean section 24 (1.8) 24 (1.7) 1.00 (0.57–1.75) 0.992
Hypertensive disorders of pregnancy 11 (0.8) 12 (0.9) 1.09 (0.48–2.46) >0.999
Malaria 6 (0.4) 3 (0.2) 0.50 (0.12–1.99) 0.314
Other infections 10 (0.8) 6 (0.4) 0.60 (0.22–1.64) 0.330
Anaemia 3 (0.2) 2 (0.2) 0.66 (0.11–3.97) 0.687
Placenta praevia 2 (0.2) 3 (0.2) 1.50 (0.25–8.94) >0.999
Antepartum haemorrhage 3 (0.2) 4 (0.3) 1.33 (0.30–5.93) >0.999
Preterm labour 16 (1.2) 6 (0.4) 0.31 (0.11–0.85) 0.034
Preterm premature rupture of membranes 13 (1.0) 4 (0.3) 0.31 (0.10–0.94) 0.030
Prolonged prelabour rupture of membranes 2 (0.2) 1 (0.1) 0.50 (0.05–5.49) 0.624
Induction of labour (post-dates) 0 (0.0) 4 (0.3) – 0.125
Postpartum haemorrhage 16 (1.2) 23 (1.7) 1.43 (0.76–2.70) 0.333
Otherd 3 (0.2) 3 (0.2) 1.00 (0.20–4.93) >0.999
Neonatal 74 (5.4) 77 (5.6) 1.04 (0.76–1.42) 0.816
No. admittedb 61 (4.4) 67 (4.9) 1.10 (0.78–1.54) 0.599
No. of babies with two SAEs 0 (0.0) 1 (0.0) – >0.999
No. drug-related SAEs 0 (0.0) 0 (0.0) – -
Characteristics of neonatal SAEsc
Congenital abnormalitye 8 (0.6) 10 (0.7) 1.25 (0.49–3.14) 0.814
Neonatal death 19 (1.4) 11 (0.8) 0.58 (0.28–1.21) 0.140
Prematurity 15 (1.1) 9 (0.7) 0.60 (0.26–1.36) 0.227
Low birthweight 20 (1.5) 10 (0.7) 0.50 (0.23–1.06) 0.069
Infection 42 (3.1) 37 (2.7) 0.88 (0.57–1.36) 0.570
Birth asphyxia 16 (1.2) 18 (1.3) 1.12 (0.57–2.19) 0.736
Meconium aspiration syndrome 10 (0.7) 14 (1.0) 1.40 (0.62–3.13) 0.416
Cephalohaematoma 3 (0.2) 6 (0.4) 1.99 (0.50–7.96) 0.507
Jaundice 2 (0.2) 3 (0.2) 1.50 (0.25–8.94) >0.999
All non-serious adverse events (AEs) 240 (17.5) 216 (15.7) 0.94 (0.80–1.11) 0.456
No. women with two AEs 10 (0.7) 13 (0.9) 1.30 (0.57–2.95) 0.535
No. drug-related maternal AEf 149 (10.8) 144 (10.5) 0.96 (0.78–1.20) 0.737
No. drug-related formal withdrawalsg 7 (0.5) 8 (0.6) 1.14 (0.41–3.13) >0.999
No. women with two drug-related AEs 3 (0.2) 9 (0.7) 2.99 (0.81–11.03) 0.145
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Table 4 Safety of trial interventions: adverse events (Continued)
Characteristics of drug-related maternal AEs
Vomiting 82 (6.0) 74 (5.4) 0.90 (0.66–1.22) 0.498
Dizziness 56 (4.1) 33 (2.4) 0.59 (0.39–0.90) 0.013
Nausea 37 (2.7) 43 (3.1) 1.16 (0.75–1.79) 0.544
Pruritus 17 (1.2) 9 (0.7) 0.53 (0.24–1.18) 0.120
Weakness 13 (1.0) 13 (0.9) 1.00 (0.46–2.14) 0.994
Abdominal pain 3 (0.2) 12 (0.9) 4.32 (1.23–15.13) 0.021
Headache 8 (0.6) 5 (0.4) 0.62 (0.20–1.90) 0.422
Diarrhoea 1 (0.1) 3 (0.2) 2.99 (0.31–28.7) 0.625
Facial swelling (mild) 3 (0.2) 1 (0.1) 0.33 (0.04–3.19) 0.374
Feeling hot 3 (0.2) 0 (0.0) – 0.124
Dyspepsia 0 (0.0) 4 (0.3) – 0.125
Loss of appetite 0 (0.0) 2 (0.2) – 0.500
Other 5 (0.4) 7 (0.1) 1.40 (0.44–4.39) 0.774
Data are n (%). Five women with SAEs, and six with drug-related AEs (occurring after administration of the first, correct, treatment) had unintentional treatment
crossover and were analysed as per original assignment. P <0.05 marked in bold.
aInclude stillbirths and miscarriages.
bAdmission/prolongation of admission because of SAE.
cSAE reported because of one or more of the following.
dTrauma (2), vaginal haematoma (1), attempted suicide (1), gestational diabetes (1), hyperemesis gravidarum, possible appendicitis (1).
eMajor: spina bifida (1), talipes equinovarus (5), cheilo- and palatoschisis [one with concomitant polydactyly] (2), prune belly syndrome (1), hypospadias (1), trisomy 21
(1), pulmonary atresia (1), multiple abnormalities of unknown cause (2), unilateral hand deformity (1) polydactyly (1), oligodactyly (1); minor: pectus carinatum (1).
fIn the control group 19 women reported a reaction after taking placebo tablets.
gAll due to nausea/vomiting after taking the study medication.
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might derive most benefit from interventions such as
IPTp, especially when combined with early attendance
at antenatal clinics [44].
Conclusions
Our findings suggest that IPTp with SPAZ reduces the
risk of LBW in a setting of low-to-moderate malaria
prevalence; it might have greater benefit in areas with
higher malaria burden. Future research will evaluate the
impact of SPAZ on pneumococcal antibiotic resistance,
the latter being a potential barrier to implementation.
Promising interventions to reduce LBW and PTD in
countries such as PNG are rare; SPAZ is one such candi-
date worthy of further evaluation.
Additional files
Additional file 1: Study protocol.
Additional file 2: CONSORT checklist.
Additional file 3: Map of study area including location of
recruitment antenatal clinics.
Additional file 4: Table S1. Comparison of baseline characteristics of
study participants included in, and excluded from, the intention-to-treat
(ITT) birthweight analysis. Table S2. Comparison of baseline characteristics
of study participants excluded from the ITT birthweight analysis, by treat-
ment arm (n = 754). Table S3. Factors associated with low birthweight on
crude analysis. Table S4. Stratified analysis of low birthweight for gravidity,
maternal height, maternal ethnic parentage, and bed net use before
enrolment, by treatment group.Abbreviations
AEs: Adverse events; ARR: Absolute risk reduction; AZ: Azithromycin;
CQ: Chloroquine; DSMB: Data Safety Monitoring Board; GA: Gestational
age; IPTp: Intermittent preventive treatment of malaria in pregnancy;
ITT: Intention-to-treat; LBW: Low birthweight; P.f.: Plasmodium falciparum;
PNG: Papua New Guinea; PNGIMR: PNG Institute of Medical Research;
PP: Per-protocol; PTD: Pre-term delivery; P.v.: P. vivax; RR: Risk ratios;
SAE: Serious adverse event; SPAZ: AZ combined with SP; SP:
Sulphadoxine-pyrimethamine; STIs: Sexually transmitted infections.
Competing interests
All authors declare that they have no competing interests.
Authors’ contributions
SJR, IM, PS, CM, and AB conceived and designed the study. MO, RW, HWU,
SH, DSi, and IB supervised enrolment and follow-up of patients. AJU, LJR,
ARU, EL, and CK supervised and conducted laboratory procedures. HWU, SJR,
IM, CSNLWS, RW, MO, LJR, and DSu verified, analysed, and interpreted the
data. HWU and SJR drafted the original version of the manuscript. All authors
participated in the writing of the manuscript, and read and approved the
final draft.
Acknowledgements
We thank the participating women and their families; the PNGIMR clinical,
administrative, logistics, and laboratory staff; the staff at all participating
health centres and hospitals; Lisa Lansfield, Hector Morris, John Bolnga,
Jaume Ordi, Albert Serra Pou, Eline Kattenberg, Celine Barnadas, Andrew
Raiko, Jane Walker, Sylvia Soso, Nola Ndrewei, Clare Ryan, and Jacob Kumai;
DSMB members Julie Simpson and James McCarthy; independent clinician
(drug safety) Moses Laman; independent clinical monitor Honor Rose; and
Christalla Hajisava. This study was funded by the Malaria in Pregnancy
Consortium, through a grant from the Bill & Melinda Gates Foundation
(46099); the Pregvax Consortium, through a grant from the European Union’s
Seventh Framework Programme FP7-2007-HEALTH (PREGVAX 201588) and
the Spanish Government (EUROSALUD 2008 Programme); and Pfizer Inc.,
through an investigator-initiated research grant (WS394663). LJR received a
National Health and Medical Research Council (NHMRC) Early Career
Unger et al. BMC Medicine  (2015) 13:9 Page 15 of 16Fellowship (#1016443). IM received an NHMRC Senior Research Fellowship
(#1043345). The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Author details
1Department of Medicine (Royal Melbourne Hospital), The University of
Melbourne, Post Office Royal Melbourne Hospital, Parkville, Victoria 3050,
Australia. 2Papua New Guinea Institute of Medical Research, PO Box 60,
Goroka, Eastern Highlands Province 441, Papua New Guinea. 3Walter and
Eliza Hall Institute (WEHI), Parkville, Victoria 3052, Australia. 4Institute of
Tropical Medicine, Nationalestraat 155, 2000 Antwerpen, Belgium. 5Barcelona
Centre for International Health Research (CRESIB), Hospital Clínic-Universitat
de Barcelona, Rossello, 132, 7th floor, 08036 Barcelona, Spain. 6Australian
Institute of Tropical Health and Medicine, Faculty of Medicine, Health, and
Molecular Sciences, James Cook University, Townsville, Queensland 4811,
Australia. 7Department of Medical Biology, The University of Melbourne,
Parkville, Victoria 3010, Australia.
Received: 31 October 2014 Accepted: 16 December 2014
References
1. Guyatt HL, Snow RW. Impact of malaria during pregnancy on low birth
weight in sub-Saharan Africa. Clin Microbiol Rev. 2004;17:760–9.
2. Umbers AJ, Aitken EH, Rogerson SJ. Malaria in pregnancy: small babies, big
problem. Trends Parasitol. 2011;27:168–75.
3. Desai M, ter Kuile FO, Nosten F, McGready R, Asamoa K, Brabin B, et al.
Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis.
2007;7:93–104.
4. Brabin BJ, Romagosa C, Abdelgalil S, Menendez C, Verhoeff FH, McGready R,
et al. The sick placenta-the role of malaria. Placenta. 2004;25:359–78.
5. Aitken EH, Mbewe B, Luntamo M, Maleta K, Kulmala T, Friso MJ, et al.
Antibodies to chondroitin sulfate A-binding infected erythrocytes: dynamics
and protection during pregnancy in women receiving intermittent preventive
treatment. J Infect Dis. 2010;201:1316–25.
6. Dellicour S, Tatem AJ, Guerra CA, Snow RW, ter Kuile FO. Quantifying the
number of pregnancies at risk of malaria in 2007: a demographic study.
PLoS Med. 2010;7:e1000221.
7. World Health Organization. WHO policy brief for the implementation of
intermittent preventive treatment in malaria in pregnancy using
sulfadoxine-pyrimethamine (IPTp-SP) (January 2014). Geneva: World Health
Organization; 2014.
8. Taylor SM, Antonia AL, Chaluluka E, Mwapasa V, Feng G, Molyneux ME, et al.
Antenatal receipt of sulfadoxine-pyrimethamine does not exacerbate
pregnancy-associated malaria despite the expansion of drug-resistant Plas-
modium falciparum: clinical outcomes from the QuEERPAM study. Clin In-
fect Dis. 2012;55:42–50.
9. Chico RM, Chandramohan D. Intermittent preventive treatment of malaria
in pregnancy: at the crossroads of public health policy. Trop Med Int Health.
2011;16:774–85.
10. Salman S, Rogerson SJ, Kose K, Griffin S, Gomorai S, Baiwog F, et al.
Pharmacokinetic properties of azithromycin in pregnancy. Antimicrob
Agents Chemother. 2010;54:360–6.
11. Luntamo M, Kulmala T, Mbewe B, Cheung YB, Maleta K, Ashorn P. Effect of
repeated treatment of pregnant women with sulfadoxine-pyrimethamine
and azithromycin on preterm delivery in Malawi: a randomized controlled
trial. Am J Trop Med Hyg. 2010;83:1212–20.
12. Luntamo M, Rantala AM, Meshnick SR, Cheung YB, Kulmala T, Maleta K, et al.
The effect of monthly sulfadoxine-pyrimethamine, alone or with azithromycin,
on PCR-diagnosed malaria at delivery: a randomized controlled trial. PLoS One.
2012;7:e41123.
13. Chico RM, Hack BB, Newport MJ, Ngulube E, Chandramohan D. On the
pathway to better birth outcomes? A systematic review of azithromycin and
curable sexually transmitted infections. Expert Rev Anti Infect Ther.
2013;11:1303–32.
14. Sidhu AB, Sun Q, Nkrumah LJ, Dunne MW, Sacchettini JC, Fidock DA. In
vitro efficacy, resistance selection, and structural modeling studies implicate
the malarial parasite apicoplast as the target of azithromycin. J Biol Chem.
2007;282:2494–504.
15. Chandra RS, Orazem J, Ubben D, Duparc S, Robbins J, Vandenbroucke P.
Creative solutions to extraordinary challenges in clinical trials: methodologyof a phase III trial of azithromycin and chloroquine fixed-dose combination
in pregnant women in Africa. Malar J. 2013;12:122.
16. Mueller I, Rogerson S, Mola GD, Reeder JC. A review of the current state of
malaria among pregnant women in Papua New Guinea. P N G Med J.
2008;51:12–6.
17. Rijken MJ, McGready R, Boel ME, Poespoprodjo R, Singh N, Syafruddin D,
et al. Malaria in pregnancy in the Asia-Pacific region. Lancet Infect Dis.
2012;12:75–88.
18. Barnadas C, Senn N, Iga J, Timinao L, Javati S, Malau E, et al. Plasmodium
falciparum and Plasmodium vivax genotypes and efficacy of intermittent
preventive treatment in Papua New Guinea. Antimicrob Agents Chemother.
2014;58:6958–61.
19. Wong RP, Karunajeewa H, Mueller I, Siba P, Zimmerman PA, Davis TM. Molecular
assessment of Plasmodium falciparum resistance to antimalarial drugs in Papua
New Guinea using an extended ligase detection reaction fluorescent
microsphere assay. Antimicrob Agents Chemother. 2010;55:798–805.
20. Wong RP, Lautu D, Tavul L, Hackett SL, Siba P, Karunajeewa HA, et al. In vitro
sensitivity of Plasmodium falciparum to conventional and novel antimalarial
drugs in Papua New Guinea. Trop Med Int Health. 2010;15:342–9.
21. Naidoo I, Roper C. Mapping ‘partially resistant’, ‘fully resistant’, and ‘super
resistant’ malaria. Trends Parasitol. 2013;29:505–15.
22. Chico RM, Chandramohan D. Azithromycin plus chloroquine: combination
therapy for protection against malaria and sexually transmitted infections in
pregnancy. Expert Opin Drug Metab Toxicol. 2011;7:1153–67.
23. Schultz L, Wapling J, Mueller I, Ntsuke PO, Senn N, Nale J, et al. Multilocus
haplotypes reveal variable levels of diversity and population structure of
Plasmodium falciparum in Papua New Guinea, a region of intense perennial
transmission. Malar J. 2010;9:336.
24. Vallely A, Page A, Dias S, Siba P, Lupiwa T, Law G, et al. The prevalence of
sexually transmitted infections in Papua New Guinea: a systematic review
and meta-analysis. PLoS One. 2010;5:e15586.
25. National Competency Training Project. Malaria diagnosis and the new
treatment protocol: a training manual for health workers in Papua New
Guinea. Port Moresby: Birdwing Publishing; 2010.
26. Loughna P, Chitty L, Evans T, Chudleigh T. Fetal size and dating: charts
recommended for clinical obstetric practice. Ultrasound. 2009;17:161–7.
27. Hadlock FP, Deter RL, Harrist RB, Park SK. Estimating fetal age: computer-
assisted analysis of multiple fetal growth parameters. Radiology.
1984;152:497–501.
28. Rosanas-Urgell A, Mueller D, Betuela I, Barnadas C, Iga J, Zimmerman PA,
et al. Comparison of diagnostic methods for the detection and
quantification of the four sympatric Plasmodium species in field samples
from Papua New Guinea. Malar J. 2010;9:361.
29. Wangnapi RA, Soso S, Unger HW, Sawera C, Ome M, Umbers AJ, et al.
Prevalence and risk factors for Chlamydia trachomatis, Neisseria
gonorrhoeae and Trichomonas vaginalis infection in pregnant women in
Papua New Guinea. Sex Transm Infect. 2014 [Epub ahead of print].
30. Ismail MR, Ordi J, Menendez C, Ventura PJ, Aponte JJ, Kahigwa E, et al.
Placental pathology in malaria: a histological, immunohistochemical, and
quantitative study. Hum Pathol. 2000;31:85–93.
31. Rogerson SJ, Pollina E, Getachew A, Tadesse E, Lema VM, Molyneux ME.
Placental monocyte infiltrates in response to Plasmodium falciparum
malaria infection and their association with adverse pregnancy outcomes.
Am J Trop Med Hyg. 2003;68:115–9.
32. Rijken MJ, Rijken JA, Papageorghiou AT, Kennedy SH, Visser GH, Nosten F,
et al. Malaria in pregnancy: the difficulties in measuring birthweight. BJOG.
2011;118:671–8.
33. Zou G. A modified Poisson regression approach to prospective studies with
binary data. Am J Epidemiol. 2004;159:702–6.
34. Rubin DB. Multiple imputations for nonresponse in surveys. New York: Wiley
& Sons; 1987.
35. van den Broek NR, White SA, Goodall M, Ntonya C, Kayira E, Kafulafula G,
et al. The APPLe study: a randomized, community-based, placebo-controlled
trial of azithromycin for the prevention of preterm birth, with meta-analysis.
PLoS Med. 2009;6:e1000191.
36. Kayentao K, Garner P, van Eijk AM, Naidoo I, Roper C, Mulokozi A, et al.
Intermittent preventive therapy for malaria during pregnancy using 2 vs 3
or more doses of sulfadoxine-pyrimethamine and risk of low birth weight in
Africa: systematic review and meta-analysis. JAMA. 2013;309:594–604.
37. Radeva-Petrova D, Kayentao K, Ter Kuile FO, Sinclair D, Garner P. Drugs for
preventing malaria in pregnant women in endemic areas: any drug
Unger et al. BMC Medicine  (2015) 13:9 Page 16 of 16regimen versus placebo or no treatment. Cochrane Database Syst Rev.
2014;10, CD000169.
38. Zarogoulidis P, Papanas N, Kioumis I, Chatzaki E, Maltezos E, Zarogoulidis K.
Macrolides: from in vitro anti-inflammatory and immunomodulatory
properties to clinical practice in respiratory diseases. Eur J Clin Pharmacol.
2012;68:479–503.
39. Harrington WE, Mutabingwa TK, Muehlenbachs A, Sorensen B, Bolla MC,
Fried M, et al. Competitive facilitation of drug-resistant Plasmodium
falciparum malaria parasites in pregnant women who receive preventive
treatment. Proc Natl Acad Sci U S A. 2009;106:9027–32.
40. Skalet AH, Cevallos V, Ayele B, Gebre T, Zhou Z, Jorgensen JH, et al.
Antibiotic selection pressure and macrolide resistance in nasopharyngeal
Streptococcus pneumoniae: a cluster-randomized clinical trial. PLoS Med.
2010;7:e1000377.
41. Lund M, Pasternak B, Davidsen RB, Feenstra B, Krogh C, Diaz LJ, et al. Use of
macrolides in mother and child and risk of infantile hypertrophic pyloric
stenosis: nationwide cohort study. BMJ. 2014;348:g1908.
42. Brabin B, Piper C. Anaemia- and malaria-attributable low birthweight in two
populations in Papua New Guinea. Ann Hum Biol. 1997;24:547–55.
43. National Department of Health. Standard management of sexually
transmitted infections and genital conditions in Papua New Guinea. Port
Moresby: National Department of Health; 2006.
44. Vallely LM, Homiehombo P, Kelly AM, Vallely A, Homer CS, Whittaker A.
Exploring women’s perspectives of access to care during pregnancy and
childbirth: a qualitative study from rural Papua New Guinea. Midwifery.
2013;29:1222–9.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
